Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Solutions

    Solutions

    Our solutions span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read more
    Solutions
    Clinical & Scientific OperationsConsultingEarly ClinicalLaboratoriesLanguage ServicesMedical ImagingSite & Patient Solutions Strategic SolutionsTechnologies
    End-to-end services, operational model and technology to deliver customised solutions.
    Decentralised Clinical Trial Solutions

    End-to-end services, operational model and technology to deliver customised solutions.

    Optimising real world data to drive effective outcomes and achieve regulatory authorisation.
    Real World Intelligence®

    Optimising real world data to drive effective outcomes and achieve regulatory authorisation.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Sectors
    BiosimilarsBiotechGovernment and Public HealthMedical DevicePharmaceuticals
    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read more
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyPaediatricsRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
    Vaccines

    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read more
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Establishing a platform for improvement
    Diversity and inclusion in clinical trials

    Establishing a platform for improvement

    Patient focused research for better outcomes.
    Decentralised clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    News & Events
    Press releasesIn the NewsMediakitAwardsEventsWebinarsSocial media
    2-6 June 2023
    ASCO 2023 conference

    2-6 June 2023

    27 June 2023
    Webinar: Minimising the impact of cross-cultural differences in COA translations

    27 June 2023

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read more
    About ICON
    Company historyHealthcare IntelligenceICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON CARES is our commitment to making a positive impact on our people, environment and our community.
    Environmental, Social and Governance

    ICON CARES is our commitment to making a positive impact on our people, environment and our community.

    Clinical Research. Evolved.
    Healthcare Intelligence

    Clinical Research. Evolved.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 11 November 2020

    ICON Releases First Environmental, Social and Governance Report

    ICON announces the release of its first Environmental, Social and Governance (ESG) Report.

  • 30 October 2020

    ICON plc to present at the 29th Annual Credit Suisse Virtual Healthcare Conference and Evercore ISI HealthCONx Conference

    ICON plc to present at the 29th Annual Credit Suisse Virtual Healthcare Conference and Evercore ISI HealthCONx Conference

  • 21 October 2020

    ICON Reports Third Quarter 2020 Results

    Quarter 3 reported revenue of $701.7 million representing a year on year decrease of 1.2% and 13.1% increase on Quarter 2 2020.

  • 19 October 2020

    BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response

    To help strengthen US emergency preparedness and response. ICON continues as part of BARDA’s exclusive Medical Countermeasures Clinical Studies Network.

  • 7 October 2020

    ICON wins Best CRO at the Vaccine Industry Excellence Awards

    This marks the third time ICON plc has won the award for excellence in vaccine research. The company has been named as a finalist every year since 2011.

  • 3 September 2020

    ICON launches Accellacare a global clinical research network focused on increasing patient recruitment with a patient centric approach

    Enhances ICON’s ability to offer customers integrated solutions of patient assessments at site and in-home for decentralised trials.

  • 2 September 2020

    ICON plc to Present at Wells Fargo 2020 Virtual Global Healthcare Conference and Baird 2020 Global Healthcare Conference

    Thursday, September 10, 2020 at 09.05am EDT.

  • 21 August 2020

    Forbes names ICON in list of Best Employers in America for Women

    ICON recognised as top employer for women in anonymous survey of 75,000 employees.

  • 22 July 2020

    ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting

    Dublin, Ireland, July 22, 2020

  • 22 July 2020

    ICON Reports Second Quarter 2020 Results

    Quarter 2 reported revenue of $620.2 million representing a year on year decrease of 10.8% or 10.3% on a constant currency basis.

  • 1
  • ...
  • 4
  • 5
  • 6
  • 7
  • 8
  • ...
  • 16
In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON spokespeople
  • Awards
  • Events
    • Industry events
      • ASCO 2023
      • BioEquity Europe
      • FT US Pharma and Biotech Summit
    • Webinars
    • Workshops
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What’s happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Social media dashboard
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2023 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies
  • International Transfers

Connect with us

Contact usSubmit proposal requestUpdate Email PreferencesGlobal office locatorICON on social media